{"id":21419,"date":"2025-01-13T21:57:00","date_gmt":"2025-01-13T13:57:00","guid":{"rendered":"https:\/\/flcube.com\/?p=21419"},"modified":"2025-01-13T21:57:01","modified_gmt":"2025-01-13T13:57:01","slug":"mabworks-biotech-licenses-anti-april-mab-to-climb-bio-for-global-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21419","title":{"rendered":"Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development"},"content":{"rendered":"\n<p>China-based Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070) has entered into a licensing deal with US firm Climb Bio, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/CLYM:NASDAQ\">NASDAQ: CLYM<\/a>). Under the agreement, Climb Bio will take exclusive development, manufacturing, and sales rights to Mabworks&#8217; MIL116 (now CLYM116), an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody (mAb) primarily designed to treat IgA nephropathy, in territories outside of Greater China. This strategic partnership aims to accelerate the global development and commercialization of CLYM116, addressing a significant unmet medical need in nephrology.<\/p>\n\n\n\n<p><strong>Agreement Terms and Financials<\/strong><br>Under the terms of the agreement, Climb Bio will make an upfront cash payment of USD 9 million to Mabworks. Additionally, Climb Bio is committed to making certain additional payments upon the achievement of specified development, regulatory, and commercial milestones. Mabworks will also receive low- to mid-single digit tiered royalties on net sales of CLYM116 outside of Greater China. This financial structure provides Mabworks with immediate funding to support its ongoing research and development efforts, while also offering the potential for significant additional revenues based on the success of CLYM116 in the global market.<\/p>\n\n\n\n<p><strong>Therapeutic Potential of CLYM116<\/strong><br>MIL116, now known as CLYM116, is an anti-APRIL monoclonal antibody designed to treat IgA nephropathy, a common form of kidney disease characterized by the deposition of IgA immune complexes in the glomeruli of the kidney. APRIL is a key cytokine involved in the pathogenesis of IgA nephropathy, and targeting APRIL with CLYM116 has the potential to reduce inflammation and slow the progression of kidney damage. This innovative approach offers a new therapeutic option for patients with IgA nephropathy, who currently have limited treatment choices.<\/p>\n\n\n\n<p><strong>Future Prospects<\/strong><br>The licensing deal between Beijing Mabworks Biotech and Climb Bio represents a significant step forward in the development of novel treatments for IgA nephropathy. By leveraging Climb Bio&#8217;s expertise in global drug development and commercialization, the partnership aims to bring CLYM116 to patients in need around the world. This collaboration not only enhances the potential for CLYM116 to reach a broader patient population but also underscores the growing trend of international partnerships in the biopharmaceutical industry to address global health challenges.<a href=\"https:\/\/flcube.com\/\"><\/a><a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070) has entered into a licensing deal&#8230;<\/p>\n","protected":false},"author":1,"featured_media":21420,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3137,1938,3138],"class_list":["post-21419","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-climb-bio","tag-mabworks-biotech","tag-nasdaq-clym"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070) has entered into a licensing deal with US firm Climb Bio, Inc. (NASDAQ: CLYM). Under the agreement, Climb Bio will take exclusive development, manufacturing, and sales rights to Mabworks&#039; MIL116 (now CLYM116), an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody (mAb) primarily designed to treat IgA nephropathy, in territories outside of Greater China. This strategic partnership aims to accelerate the global development and commercialization of CLYM116, addressing a significant unmet medical need in nephrology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21419\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development\" \/>\n<meta property=\"og:description\" content=\"China-based Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070) has entered into a licensing deal with US firm Climb Bio, Inc. (NASDAQ: CLYM). Under the agreement, Climb Bio will take exclusive development, manufacturing, and sales rights to Mabworks&#039; MIL116 (now CLYM116), an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody (mAb) primarily designed to treat IgA nephropathy, in territories outside of Greater China. This strategic partnership aims to accelerate the global development and commercialization of CLYM116, addressing a significant unmet medical need in nephrology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21419\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-13T13:57:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-13T13:57:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1324.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"618\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21419#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21419\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development\",\"datePublished\":\"2025-01-13T13:57:00+00:00\",\"dateModified\":\"2025-01-13T13:57:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21419\"},\"wordCount\":365,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21419#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1324.png\",\"keywords\":[\"Climb Bio\",\"Mabworks Biotech\",\"NASDAQ: CLYM\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21419#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21419\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21419\",\"name\":\"Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21419#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21419#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1324.png\",\"datePublished\":\"2025-01-13T13:57:00+00:00\",\"dateModified\":\"2025-01-13T13:57:01+00:00\",\"description\":\"China-based Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070) has entered into a licensing deal with US firm Climb Bio, Inc. (NASDAQ: CLYM). Under the agreement, Climb Bio will take exclusive development, manufacturing, and sales rights to Mabworks' MIL116 (now CLYM116), an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody (mAb) primarily designed to treat IgA nephropathy, in territories outside of Greater China. This strategic partnership aims to accelerate the global development and commercialization of CLYM116, addressing a significant unmet medical need in nephrology.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21419#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21419\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21419#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1324.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1324.png\",\"width\":1000,\"height\":618,\"caption\":\"Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21419#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070) has entered into a licensing deal with US firm Climb Bio, Inc. (NASDAQ: CLYM). Under the agreement, Climb Bio will take exclusive development, manufacturing, and sales rights to Mabworks' MIL116 (now CLYM116), an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody (mAb) primarily designed to treat IgA nephropathy, in territories outside of Greater China. This strategic partnership aims to accelerate the global development and commercialization of CLYM116, addressing a significant unmet medical need in nephrology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21419","og_locale":"en_US","og_type":"article","og_title":"Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development","og_description":"China-based Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070) has entered into a licensing deal with US firm Climb Bio, Inc. (NASDAQ: CLYM). Under the agreement, Climb Bio will take exclusive development, manufacturing, and sales rights to Mabworks' MIL116 (now CLYM116), an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody (mAb) primarily designed to treat IgA nephropathy, in territories outside of Greater China. This strategic partnership aims to accelerate the global development and commercialization of CLYM116, addressing a significant unmet medical need in nephrology.","og_url":"https:\/\/flcube.com\/?p=21419","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-13T13:57:00+00:00","article_modified_time":"2025-01-13T13:57:01+00:00","og_image":[{"width":1000,"height":618,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1324.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21419#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21419"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development","datePublished":"2025-01-13T13:57:00+00:00","dateModified":"2025-01-13T13:57:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21419"},"wordCount":365,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21419#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1324.png","keywords":["Climb Bio","Mabworks Biotech","NASDAQ: CLYM"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21419#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21419","url":"https:\/\/flcube.com\/?p=21419","name":"Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21419#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21419#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1324.png","datePublished":"2025-01-13T13:57:00+00:00","dateModified":"2025-01-13T13:57:01+00:00","description":"China-based Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070) has entered into a licensing deal with US firm Climb Bio, Inc. (NASDAQ: CLYM). Under the agreement, Climb Bio will take exclusive development, manufacturing, and sales rights to Mabworks' MIL116 (now CLYM116), an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody (mAb) primarily designed to treat IgA nephropathy, in territories outside of Greater China. This strategic partnership aims to accelerate the global development and commercialization of CLYM116, addressing a significant unmet medical need in nephrology.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21419#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21419"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21419#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1324.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1324.png","width":1000,"height":618,"caption":"Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21419#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1324.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21419"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21419\/revisions"}],"predecessor-version":[{"id":21421,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21419\/revisions\/21421"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21420"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}